EIDX- NAS (USA) Also traded in: Germany
Eidos Therapeutics Inc

Not Rated

Top Ranked Predictable Companies

$122.21

0(0%) 4:00PM EST

Avg Vol (1m): 114,742

Warning! GuruFocus has detected 1 Severe Warning Sign with NAS:EIDX. Click here to check it out.

Market Cap : 4.75 B	Enterprise Value : 4.62 B	PE Ratio :	PB Ratio : 38.39

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- Insider Ownership
- Institutional Ownership
- Market Cap
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Cash Conversion Cycle
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow statement
- All Taxes Paid
- Asset Impairment Charge
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid

Eidos Therapeutics EV-to-EBIT

: -46.90 (As of Today)

View and export this data going back to 2018. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eidos Therapeutics's Enterprise Value is $4,624.80 Mil. Eidos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-98.61 Mil. Therefore, Eidos Therapeutics's EV-to-EBIT for today is -46.90.

NAS:EIDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -62.3 Med: -34.9 Max: -14.7
Current: -46.9

-62.3

-14.7

During the past 4 years, the highest EV-to-EBIT of Eidos Therapeutics was -14.70. The lowest was -62.30. And the median was -34.90.

NAS:EIDX's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Biotechnology industry.

( Industry Median: 34.52 vs. NAS:EIDX: -46.90 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Eidos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $1,824.20 Mil. Eidos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-98.61 Mil. Eidos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -5.41%.

Eidos Therapeutics EV-to-EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Eidos Therapeutics Annual Data
	Dec16	Dec17	Dec18	Dec19
EV-to-EBIT	0.00	0.00	-8.78	-53.68

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
EV-to-EBIT												-36.10	-53.68	-35.72	0.00	0.00

Competitive Comparison

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Eidos Therapeutics EV-to-EBIT Distribution

* The bar in red indicates where Eidos Therapeutics's EV-to-EBIT falls into.

Eidos Therapeutics EV-to-EBIT Calculation

Eidos Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	4624.796	/	-98.614
	=	-46.90

Eidos Therapeutics's current Enterprise Value is $4,624.80 Mil.
Eidos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was -18.653 (Dec. 2019 ) + -22.306 (Mar. 2020 ) + -28.245 (Jun. 2020 ) + -29.41 (Sep. 2020 ) = $-98.61 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Eidos Therapeutics (NAS:EIDX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Eidos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 )	=	EBIT	/	Enterprise Value (Q: Sep. 2020 )
	=	-98.614	/	1824.203866
	=	-5.41 %

Eidos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $1,824.20 Mil.
Eidos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was -18.653 (Dec. 2019 ) + -22.306 (Mar. 2020 ) + -28.245 (Jun. 2020 ) + -29.41 (Sep. 2020 ) = $-98.61 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Eidos Therapeutics EV-to-EBIT Related Terms

Eidos Therapeutics EV-to-EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Tools

Market Valuation

Economic Indicators

By Country

Articles

Submit Articles

Eidos Therapeutics EV-to-EBIT

Eidos Therapeutics EV-to-EBIT Historical Data

Eidos Therapeutics EV-to-EBIT Calculation

Eidos Therapeutics EV-to-EBIT Related Terms

Eidos Therapeutics EV-to-EBIT Headlines